Clinical Trials Browser

Phase 1/2 × tisotumab vedotin × Thoracic × Clear all

NCT02552121 2021-04-08

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms